Trump Order Fine Print Makes Pharma Firms Breathe Easy

The domestic pharma industry, which was fearing a severe impact of US President Donald Trump's drug pricing proposal, is breathing easy.

- MANU KAUSHIK

The details showed that the executive order was "weaker-than-expected" and "sketchy."

Despite vowing to end price discrimination against US patients, Trump's executive order lacked details on the punitive action against the violating pharma manufacturers, pharma analysts said.

Instead, it said that the pharma manufacturers will have to comply with the order within 30 days, failing which the US secretary of health and human services will "propose a rulemaking plan to impose most-favored-nation pricing."